Exicure achieves Phase 2 milestone for Burixafor (GPC-100); owes $1M payment to GPCR Therapeutics

EXICURE, INC.

Phase 2 trial (NCT05561751) completed; Clinical Study Report submitted to FDA on Jan 16, 2026.
Milestone payment of $1,000,000 due to GPCR Therapeutics Inc. within 30 days.
Achievement triggers improved future sublicensing income-sharing ratio for Exicure.
Milestone reflects progress in development of small-molecule CXCR4 inhibitor Burixafor (GPC-100).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.